# Presentation: 575623

## Imaging Informatics: An NCI Strategic Perspective

**Gary S. Dorfman, M.D.**
**Bethesda, MD**

## I2 Team Background:An Alternative to Business as Usual

**“****Eliminate Death and Suffering from Cancer by 2015” – The Director’s Challenge**
**Integration and Implementation Teams**
**Relatively Small Budgets**
**Create / Optimize Synergies**
**Strategic Initiatives**
**Business Plans**
**Measurable Outcomes**
**ROI**

## I2 Teams:Current Status

**I2 Bioinformatics Information Gathering**
**I2 Lung Cancer**
**Approved Business Plan**
**Awaiting Funding in 2006**
**Includes Deliverables with Imaging Informatics Implications**
**I2 Imaging**
**Most Mature – Funded in 2005**
**Significant Imaging Informatics Deliverables, Including**
**NCI Imaging Archive Infrastructure**
**Purpose-built Databases & Datasets**
**caBIG *****in vivo***** Imaging Workspace**

## Additional Background:CTWG and caBIG

**Redesigning the Clinical Trials Infrastructure**
**Role of Imaging Open**
**Potential for Imaging at the Leading Edge**
**caBIG Evolving**
**Domain and Cross-cutting Workspaces**
**Conventions, Compatibility Guidelines**
***in vivo***** Imaging Workspace **_**Congruous**_** with caBIG**
***in vivo***** Imaging Workspace **_**Targeted**_** to I2 Goals**
**Can *****in vivo***** Imaging Meet the Director’s Challenge?**
**CTWG**
**I2 & the caBIG *****in vivo***** Imaging Workspace**

## I2 Imaging:Product Lines Based on Imaging for....

**Cancer Prevention / Pre-emption**
**Early Rx Development (Phase I / II)**
**PK / PD Data**
**Late Rx Development (Phase II / III)**
**Imaging Markers of Response / Surrogates**
**Used in Go / No Go Decisions; FDA Utility**
**IGI (Phase 0 – III)**
**Replicate Pharma Trial Infrastructure; FDA Utility**
**Understanding CA Biology / Microenvironment**
**Development of Imaging Probes (Phase 0 / I)**
**Pre-clinicals; IND; Matriculation to Early Rx**
**Development of Imaging Technologies***
**Imaging Informatics***

## I2 Imaging:Development of Imaging Technologies

**Databases /Datasets (Diverse Dx & Rx, Modalities)**
**Publicly Available**
**Restricted**
**Software Tools**
**Creation**
**Optimization**
**Validation**
**Regulatory Approval**
**Standards / Harmonization Across Platforms & Manufacturers**

## I2 Imaging:Imaging Informatics

**NCI Image Archive**
**Image and Meta-data Infrastructure**
**Standards**
**Transfer, Curation, Query**
**Purpose-built Databases / Datasets**
**Infrastructural Support**
**caBIG *****in vivo***** Imaging Workspace**
**SMEs**
**Industry & Unfunded Academia**
**Specific Deliverables to Support I2 Imaging, NCI Vision (CTWG, I2 Lung CA, CIP, etc.)**
**Academically & Intellectually Engaging**

## I2 Imaging:Examples of Deliverables of Interest

**DICOM Elements / Values in CDE & EVS**
**NLP Support for Trials, etc.**
**Support of Phase 0 – III Clinical Trials**
**Distributed Over-reads (e.g., Coop Groups, CCs, SPOREs, Phase I / II Investigators, IRATs, etc.)**
**Aggregated Image Data Across Trials**
**Standards**
**Mark-ups / Annotations**
**Small Animal Imaging “DICOM”**
**Image Display and Quantitative Analysis (e.g., PET, PET/CT, Digital Mammography, etc.)**
**Acquisition Parameters / Outputs**
**Integration of Workspace Interests into DICOM Working Groups of Interest**
**Input into the NCI Image Archive**

## I2 Lung Cancer:Product Lines & Imaging Deliverables

**Tobacco Control**
**Imaging of Nicotine Addiction**
**Early Detection / Intervention**
**Imaging for Screening including Software Tools**
**IGI for Screen Detected Lesions not Amenable to “Standard Therapy”**
**Meta-data Dictionary Linking Clinical, Proteomic, Genomic, Imaging Data**
**Novel Therapeutics**
**Lung Cancer IRAT**
**Distributed Over-reads**
**Novel Signals of Response**
**Software Tool Development**
**Standardization of Acquisition and Analysis**